Skip to content

Lucentis Phase III study meets primary end-point in diabetic macular edema

Summary data from a second Phase III study of Roche’s Lucentis (ranibizumab) in patients with diabetic macular edema (DME) have shown that patients receiving the drug, compared to control subjects, were able to read at least 15 additional letters on an eye chart beyond what they were able to read at the start of the study. No new significant safety findings were observed and the company expects to provide more detailed results at the upcoming EURETINA meeting in London (May 26th-29th).